Radiation Therapy for Multiple Myeloma

Phase-Based Progress Estimates
Multiple Myeloma+6 More
Radiation Therapy - Radiation
All Sexes
What conditions do you have?

Study Summary

This trial studies the side effects of pembrolizumab and radiation therapy in treating patients with stage I-III multiple myeloma.

Eligible Conditions
  • Multiple Myeloma
  • ISS Stage II Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma

Treatment Effectiveness

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Up to 12 months after study start

Month 12
Overall survival
Month 12
Incidence of adverse events
Number of patients achieving any response
Overall response based on baseline changes on positron emission to positron emission tomography/computed tomography

Trial Safety

Trial Design

1 Treatment Group

Radiation therapy, pembrolizumab
1 of 1

Experimental Treatment

26 Total Participants · 1 Treatment Group

Primary Treatment: Radiation Therapy · No Placebo Group · Phase 1

Radiation therapy, pembrolizumabExperimental Group · 2 Interventions: Pembrolizumab, Radiation Therapy · Intervention Types: Biological, Radiation
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
Radiation Therapy
Completed Phase 3

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 12 months after study start

Who is running the clinical trial?

Merck Sharp & Dohme LLCIndustry Sponsor
3,656 Previous Clinical Trials
4,954,132 Total Patients Enrolled
37 Trials studying Multiple Myeloma
11,330 Patients Enrolled for Multiple Myeloma
Emory UniversityLead Sponsor
1,502 Previous Clinical Trials
2,677,571 Total Patients Enrolled
24 Trials studying Multiple Myeloma
1,997 Patients Enrolled for Multiple Myeloma
Mohammad K. Khan, MD, PhDPrincipal Investigator - Emory University
Emory University
3 Previous Clinical Trials
87 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have received no more than three prior therapies before being put on the current trial.
You have 1 or more osseous and/or extra-osseous lesions that can be radiated.
You have progressive, relapsed, or refractory multiple myeloma.
You are a candidate for pembrolizumab.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 22nd, 2021

Last Reviewed: November 18th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.